IDEXX Laboratories IDXX · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500Nasdaq-100
706.65
+4.53%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$4.30bn
FY2016FY2025
Net income
$1.06bn
FY2016FY2025
Free cash flow
$1.05bn
FY2016FY2025
Shareholders' equity
$1.61bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.30bn | $3.90bn | $3.66bn | $3.37bn | $3.22bn | $2.71bn | $2.41bn | $2.21bn | $1.97bn | $1.78bn |
| Gross profit | $2.66bn | $2.38bn | $2.19bn | $2.00bn | $1.89bn | $1.57bn | $1.37bn | $1.24bn | $1.10bn | $975.4m |
| Research and development | $251.2m | $219.8m | $191.0m | $254.8m | $161.0m | $141.2m | $133.2m | $117.9m | $109.2m | $101.1m |
| Operating income | $1.36bn | $1.13bn | $1.10bn | $898.8m | $932.0m | $694.5m | $552.8m | $491.3m | $413.0m | $350.2m |
| Net income | $1.06bn | $887.9m | $845.0m | $679.1m | $744.8m | $581.8m | $427.7m | $377.0m | $263.1m | $222.0m |
| Diluted earnings per share | 13.13 | 10.69 | 10.07 | 8.10 | 8.65 | 6.69 | 4.90 | 4.29 | 2.96 | 2.45 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.35bn | $3.29bn | $3.26bn | $2.75bn | $2.44bn | $2.29bn | $1.83bn | $1.54bn | $1.71bn | $1.53bn |
| Cash and short-term investments | $180.1m | $288.3m | $453.9m | $112.5m | $144.5m | $383.9m | $90.3m | $123.8m | $471.9m | $391.9m |
| Total liabilities | $1.75bn | $1.70bn | $1.78bn | $2.14bn | $1.75bn | $1.66bn | $1.65bn | $1.55bn | $1.77bn | $1.64bn |
| Debt | $847.8m | $867.6m | $947.9m | $1.35bn | $923.7m | $908.5m | $888.3m | $898.5m | $1.15bn | $1.11bn |
| Shareholders' equity | $1.61bn | $1.60bn | $1.48bn | $608.7m | $690.0m | $632.1m | $177.5m | −$9.5m | −$54.1m | −$108.4m |
| Shares outstanding | 81m | 83m | 84m | 84m | 86m | 87m | 87m | 88m | 89m | 91m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $1.18bn | $929.0m | $906.5m | $543.0m | $755.5m | $648.1m | $459.2m | $400.1m | $373.3m | $334.6m |
| Capital spending | −$124.7m | −$130.9m | −$133.6m | −$148.8m | −$119.5m | −$107.6m | −$155.2m | −$122.9m | −$76.7m | −$64.8m |
| Free cash flow | $1.05bn | $798.1m | $772.9m | $394.1m | $636.0m | $540.4m | $303.9m | $277.1m | $296.6m | $269.8m |
| Dividends paid | — | — | — | — | −$46.6m | −$51.3m | −$36.1m | — | — | — |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.22bn | $1.14bn | $1.09bn | $1.11bn | $1.11bn | $998.4m | $954.3m | $975.5m |
| Gross profit | $779.1m | $722.7m | $658.1m | $683.4m | $694.7m | $623.4m | $570.7m | $596.0m |
| Operating income | $425.6m | $362.6m | $315.6m | $354.8m | $373.0m | $316.5m | $261.7m | $303.9m |
| Net income | $338.4m | $278.4m | $248.2m | $274.6m | $294.0m | $242.7m | $216.1m | $232.8m |
| Diluted earnings per share | 4.19 | 3.45 | 3.08 | 3.40 | 3.64 | 3.01 | 2.60 | 2.80 |
| Cash from operations | $347.0m | $266.0m | $352.0m | $402.0m | $185.0m | $237.0m | $262.0m | $220.0m |
| Capital spending | −$24.0m | −$31.0m | −$29.0m | −$31.0m | −$34.0m | −$30.0m | −$39.0m | −$28.0m |
| Free cash flow | $323.0m | $235.0m | $323.0m | $371.0m | $151.0m | $207.0m | $223.0m | $192.0m |
| Total assets | $3.44bn | $3.39bn | $3.35bn | $3.39bn | $3.33bn | $3.21bn | $3.29bn | $3.35bn |
| Cash and short-term investments | $196.9m | $200.5m | $180.1m | $208.2m | $164.6m | $164.0m | $288.3m | $308.6m |
| Debt | $995.6m | $1.01bn | $874.9m | $1.01bn | $1.13bn | $962.4m | $617.6m | $894.9m |
| Shareholders' equity | $1.61bn | $1.56bn | $1.61bn | $1.56bn | $1.46bn | $1.45bn | $1.60bn | $1.62bn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 8.5% | 9.7% | 10.4% |
| Operating income | 14.8% | 14.4% | 16.3% |
| Net income | 16.0% | 12.7% | 18.6% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 61.4% | 60.6% | 60.0% | 58.7% |
| Operating margin | 30.3% | 29.4% | 28.9% | 26.4% |
| Net margin | 23.7% | 22.8% | 22.7% | 20.2% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 51.5 | 38.7 | 55.1 | 50.4 | 76.2 | 74.7 | 53.2 | 43.3 | 52.9 | 47.8 |
| Price to sales | 12.7 | 8.8 | 12.7 | 10.2 | 17.6 | 16.1 | 9.5 | 7.4 | 7.1 | 6.0 |
Market value over time
30 Sept 2016 to 16 Sept 2026, in USD
$10.26bn$41.44bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | 70% | -25% | 36% | -33% | 23% | 87% | 41% | 17% | 34% | 66% |
Dividends and splits
Per share, in the currency the company pays
Paid for 0 years.
- 2-for-1 split · 16 Jun 2015
- 2-for-1 split · 27 Nov 2007
- 2-for-1 split · 6 Jun 1995
- 2-for-1 split · 4 Oct 1993
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.